Literature DB >> 9680929

Persistent B19 parvovirus infection in pediatric malignancies.

K Broliden1, T Tolfvenstam, S Ohlsson, J I Henter.   

Abstract

BACKGROUND AND PROCEDURE: The frequency and clinical importance of parvovirus B19 infection were studied in children investigated or treated for various malignancies and cytopenias.
RESULTS: B19 infection was thus demonstrated in six out of 53 unselected children with malignancies by bone marrow examination, using the B19, DNA-specific, polymerase chain reaction (PCR). Examinations using the PCR in serum samples were equally or less sensitive than in bone marrow samples. One of the children had a persistent B19 infection during maintenance therapy for acute lymphoblastic leukemia. She developed a prolonged and severe cytopenia, and the clinical signs included facial rash, chills, high undulating fever, and pharyngitis. She also seroconverted and became B19 IgM-antibody positive during the study period.
CONCLUSIONS: Parvovirus B19 infection was detected in 10% of the children and was either asymptomatic or was associated with severe and prolonged cytopenia. Bone marrow examinations are recommended for the detection of B19 DNA in immunosuppressed children.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9680929     DOI: 10.1002/(sici)1096-911x(199808)31:2<66::aid-mpo4>3.0.co;2-x

Source DB:  PubMed          Journal:  Med Pediatr Oncol        ISSN: 0098-1532


  6 in total

1.  Prevalence of parvovirus B19 and parvovirus V9 DNA and antibodies in paired bone marrow and serum samples from healthy individuals.

Authors:  Erik D Heegaard; Bodil Laub Petersen; Carsten J Heilmann; Allan Hornsleth
Journal:  J Clin Microbiol       Date:  2002-03       Impact factor: 5.948

2.  New LightCycler PCR for rapid and sensitive quantification of parvovirus B19 DNA guides therapeutic decision-making in relapsing infections.

Authors:  T C Harder; M Hufnagel; K Zahn; K Beutel; H J Schmitt; U Ullmann; P Rautenberg
Journal:  J Clin Microbiol       Date:  2001-12       Impact factor: 5.948

3.  Direct ex vivo measurement of CD8(+) T-lymphocyte responses to human parvovirus B19.

Authors:  T Tolfvenstam; A Oxenius; D A Price; B L Shacklett; H M Spiegel; K Hedman; O Norbeck; M Levi; K Olsen; M Kantzanou; D F Nixon; K Broliden; P Klenerman
Journal:  J Virol       Date:  2001-01       Impact factor: 5.103

Review 4.  Human parvovirus B19.

Authors:  Erik D Heegaard; Kevin E Brown
Journal:  Clin Microbiol Rev       Date:  2002-07       Impact factor: 26.132

5.  Virome characterisation from Guthrie cards in children who later developed acute lymphoblastic leukaemia.

Authors:  G Bogdanovic; C Pou; M Barrientos-Somarribas; A Bjerkner; E Honkaniemi; T Allander; B Andersson; B Gustafsson
Journal:  Br J Cancer       Date:  2016-08-23       Impact factor: 7.640

6.  Investigating causes and risk factors of pre-chemotherapy viremia in acute lymphoblastic leukemia pediatric patients.

Authors:  Nivin Abdel-Azim; Lamiaa Fadel Alkilany; Zeinab Korany Hassan; Noha Gaber
Journal:  Infection       Date:  2022-07-25       Impact factor: 7.455

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.